Which has better earnings and valuation, GMAB or ARGX?

argenex has higher revenue and earnings than Genmab A/S. Genmab A/S is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genmab A/S $4.13B 4.82 $963M $1.27 25.15 argenex $4.25B 12.54 $1.29B $26.04 32.69

Is GMAB or ARGX more profitable?

argenex has a net margin of 32.19% compared to Genmab A/S's net margin of 19.08%. argenex's return on equity of 43.59% beat Genmab A/S's return on equity. Company Net Margins Return on Equity Return on Assets Genmab A/S 19.08% 14.89% 7.73% argenex 32.19% 43.59% 36.66%

Does the media refer more to GMAB or ARGX?

In the previous week, argenex had 5 more articles in the media than Genmab A/S. MarketBeat recorded 11 mentions for argenex and 6 mentions for Genmab A/S. argenex's average media sentiment score of 0.87 beat Genmab A/S's score of 0.58 indicating that argenex is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genmab A/S 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive argenex 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, NTRA or GMAB?

Genmab A/S has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Natera $2.31B 19.37 -$208.16M -$1.36 N/A Genmab A/S $4.13B 4.82 $963M $1.27 25.15

Is NTRA or GMAB more profitable?

Genmab A/S has a net margin of 19.08% compared to Natera's net margin of -7.11%. Genmab A/S's return on equity of 14.89% beat Natera's return on equity. Company Net Margins Return on Equity Return on Assets Natera -7.11% -11.38% -7.87% Genmab A/S 19.08% 14.89% 7.73%

Does the media favor NTRA or GMAB?

In the previous week, Natera had 15 more articles in the media than Genmab A/S. MarketBeat recorded 21 mentions for Natera and 6 mentions for Genmab A/S. Natera's average media sentiment score of 0.88 beat Genmab A/S's score of 0.58 indicating that Natera is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Natera 6 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genmab A/S 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor RVMD or GMAB?

In the previous week, Revolution Medicines had 6 more articles in the media than Genmab A/S. MarketBeat recorded 12 mentions for Revolution Medicines and 6 mentions for Genmab A/S. Revolution Medicines' average media sentiment score of 0.84 beat Genmab A/S's score of 0.58 indicating that Revolution Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 5 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genmab A/S 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, GMAB or BIIB?

Biogen has higher revenue and earnings than Genmab A/S. Genmab A/S is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genmab A/S $4.13B 4.82 $963M $1.27 25.15 Biogen $9.89B 3.13 $1.29B $5.65 37.14

Is GMAB or BIIB more profitable?

Genmab A/S has a net margin of 19.08% compared to Biogen's net margin of 8.32%. Genmab A/S's return on equity of 14.89% beat Biogen's return on equity. Company Net Margins Return on Equity Return on Assets Genmab A/S 19.08% 14.89% 7.73% Biogen 8.32% 11.18% 6.88%

Does the media prefer GMAB or BIIB?

In the previous week, Biogen had 2 more articles in the media than Genmab A/S. MarketBeat recorded 8 mentions for Biogen and 6 mentions for Genmab A/S. Biogen's average media sentiment score of 1.05 beat Genmab A/S's score of 0.58 indicating that Biogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genmab A/S 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Biogen 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ALNY or GMAB?

In the previous week, Alnylam Pharmaceuticals had 8 more articles in the media than Genmab A/S. MarketBeat recorded 14 mentions for Alnylam Pharmaceuticals and 6 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 0.58 beat Alnylam Pharmaceuticals' score of 0.46 indicating that Genmab A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Genmab A/S 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Genmab A/S (GMAB) Competitors

$31.94 +0.60 (+1.91%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$31.80 -0.15 (-0.45%)

As of 08/14/2026 07:53 PM Eastern

Compare

GMAB vs. ARGX, NTRA, RVMD, BIIB, and ALNY

Should you buy Genmab A/S stock or one of its competitors? Genmab A/S's main competitors and comparable companies include argenex (ARGX), Natera (NTRA), Revolution Medicines (RVMD), Biogen (BIIB), and Alnylam Pharmaceuticals (ALNY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Genmab A/S compare to argenex?

Genmab A/S (NASDAQ:GMAB) and argenex (NASDAQ:ARGX) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and media sentiment.

argenex has higher revenue and earnings than Genmab A/S. Genmab A/S is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$4.13B	4.82	$963M	$1.27	25.15
argenex	$4.25B	12.54	$1.29B	$26.04	32.69

7.1% of Genmab A/S shares are held by institutional investors. Comparatively, 60.3% of argenex shares are held by institutional investors. 1.5% of Genmab A/S shares are held by insiders. Comparatively, 2.4% of argenex shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

argenex has a net margin of 32.19% compared to Genmab A/S's net margin of 19.08%. argenex's return on equity of 43.59% beat Genmab A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	19.08%	14.89%	7.73%
argenex	32.19%	43.59%	36.66%

In the previous week, argenex had 5 more articles in the media than Genmab A/S. MarketBeat recorded 11 mentions for argenex and 6 mentions for Genmab A/S. argenex's average media sentiment score of 0.87 beat Genmab A/S's score of 0.58 indicating that argenex is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
argenex	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Genmab A/S currently has a consensus target price of $39.50, suggesting a potential upside of 23.67%. argenex has a consensus target price of $1,056.89, suggesting a potential upside of 24.15%. Given argenex's stronger consensus rating and higher possible upside, analysts plainly believe argenex is more favorable than Genmab A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92

Genmab A/S has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market. Comparatively, argenex has a beta of 0.46, suggesting that its stock price is 54% less volatile than the broader market.

Summary

argenex beats Genmab A/S on 16 of the 17 factors compared between the two stocks.

How does Genmab A/S compare to Natera?

Natera (NASDAQ:NTRA) and Genmab A/S (NASDAQ:GMAB) are both large-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends.

Natera has a beta of 1.51, meaning that its stock price is 51% more volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market.

Genmab A/S has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Natera	$2.31B	19.37	-$208.16M	-$1.36	N/A
Genmab A/S	$4.13B	4.82	$963M	$1.27	25.15

In the previous week, Natera had 15 more articles in the media than Genmab A/S. MarketBeat recorded 21 mentions for Natera and 6 mentions for Genmab A/S. Natera's average media sentiment score of 0.88 beat Genmab A/S's score of 0.58 indicating that Natera is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Natera	6 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Genmab A/S has a net margin of 19.08% compared to Natera's net margin of -7.11%. Genmab A/S's return on equity of 14.89% beat Natera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Natera	-7.11%	-11.38%	-7.87%
Genmab A/S	19.08%	14.89%	7.73%

99.9% of Natera shares are owned by institutional investors. Comparatively, 7.1% of Genmab A/S shares are owned by institutional investors. 5.1% of Natera shares are owned by company insiders. Comparatively, 1.5% of Genmab A/S shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Natera currently has a consensus price target of $319.38, indicating a potential upside of 3.05%. Genmab A/S has a consensus price target of $39.50, indicating a potential upside of 23.67%. Given Genmab A/S's stronger consensus rating and higher probable upside, analysts plainly believe Genmab A/S is more favorable than Natera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Natera	1 Sell rating(s)	4 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.82
Genmab A/S	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85

Summary

Genmab A/S beats Natera on 9 of the 17 factors compared between the two stocks.

How does Genmab A/S compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and Genmab A/S (NASDAQ:GMAB) are both large-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.

Revolution Medicines has a beta of 1.39, indicating that its stock price is 39% more volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market.

In the previous week, Revolution Medicines had 6 more articles in the media than Genmab A/S. MarketBeat recorded 12 mentions for Revolution Medicines and 6 mentions for Genmab A/S. Revolution Medicines' average media sentiment score of 0.84 beat Genmab A/S's score of 0.58 indicating that Revolution Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	5 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Genmab A/S has a net margin of 19.08% compared to Revolution Medicines' net margin of 0.00%. Genmab A/S's return on equity of 14.89% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-88.20%	-57.85%
Genmab A/S	19.08%	14.89%	7.73%

Genmab A/S has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	N/A	N/A	-$1.13B	-$8.82	N/A
Genmab A/S	$4.13B	4.82	$963M	$1.27	25.15

Revolution Medicines presently has a consensus target price of $161.79, suggesting a potential downside of 20.58%. Genmab A/S has a consensus target price of $39.50, suggesting a potential upside of 23.67%. Given Genmab A/S's higher probable upside, analysts plainly believe Genmab A/S is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.91
Genmab A/S	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85

94.3% of Revolution Medicines shares are owned by institutional investors. Comparatively, 7.1% of Genmab A/S shares are owned by institutional investors. 7.6% of Revolution Medicines shares are owned by company insiders. Comparatively, 1.5% of Genmab A/S shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Genmab A/S beats Revolution Medicines on 8 of the 15 factors compared between the two stocks.

How does Genmab A/S compare to Biogen?

Genmab A/S (NASDAQ:GMAB) and Biogen (NASDAQ:BIIB) are both large-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings.

Genmab A/S has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market. Comparatively, Biogen has a beta of 0.17, meaning that its share price is 83% less volatile than the broader market.

7.1% of Genmab A/S shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by company insiders. Comparatively, 0.3% of Biogen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Biogen had 2 more articles in the media than Genmab A/S. MarketBeat recorded 8 mentions for Biogen and 6 mentions for Genmab A/S. Biogen's average media sentiment score of 1.05 beat Genmab A/S's score of 0.58 indicating that Biogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Biogen	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Genmab A/S has a net margin of 19.08% compared to Biogen's net margin of 8.32%. Genmab A/S's return on equity of 14.89% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	19.08%	14.89%	7.73%
Biogen	8.32%	11.18%	6.88%

Genmab A/S presently has a consensus price target of $39.50, indicating a potential upside of 23.67%. Biogen has a consensus price target of $227.07, indicating a potential upside of 8.22%. Given Genmab A/S's stronger consensus rating and higher possible upside, analysts plainly believe Genmab A/S is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85
Biogen	1 Sell rating(s)	13 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.58

Biogen has higher revenue and earnings than Genmab A/S. Genmab A/S is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$4.13B	4.82	$963M	$1.27	25.15
Biogen	$9.89B	3.13	$1.29B	$5.65	37.14

Summary

Genmab A/S and Biogen tied by winning 8 of the 16 factors compared between the two stocks.

How does Genmab A/S compare to Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Genmab A/S (NASDAQ:GMAB) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment.

Alnylam Pharmaceuticals has a beta of 0.3, meaning that its share price is 70% less volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market.

Alnylam Pharmaceuticals currently has a consensus target price of $393.86, indicating a potential upside of 72.25%. Genmab A/S has a consensus target price of $39.50, indicating a potential upside of 23.67%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Alnylam Pharmaceuticals is more favorable than Genmab A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.92
Genmab A/S	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85

93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 7.1% of Genmab A/S shares are owned by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are owned by insiders. Comparatively, 1.5% of Genmab A/S shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Alnylam Pharmaceuticals had 8 more articles in the media than Genmab A/S. MarketBeat recorded 14 mentions for Alnylam Pharmaceuticals and 6 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 0.58 beat Alnylam Pharmaceuticals' score of 0.46 indicating that Genmab A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Genmab A/S	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Genmab A/S has a net margin of 19.08% compared to Alnylam Pharmaceuticals' net margin of 15.26%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Genmab A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%
Genmab A/S	19.08%	14.89%	7.73%

Genmab A/S has higher revenue and earnings than Alnylam Pharmaceuticals. Genmab A/S is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$3.71B	8.24	$313.75M	$5.38	42.50
Genmab A/S	$4.13B	4.82	$963M	$1.27	25.15

Summary

Alnylam Pharmaceuticals beats Genmab A/S on 11 of the 17 factors compared between the two stocks.

Get Genmab A/S News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GMAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GMAB vs. The Competition

Export

Metric	Genmab A/S	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$19.92B	$3.71B	$7.02B	$13.06B
Dividend Yield	N/A	3.69%	2.57%	10.45%
P/E Ratio	25.15	10.78	271.27	25.33
Price / Sales	4.82	1,268.77	588.55	78.45
Price / Cash	19.47	102.88	70.48	50.90
Price / Book	3.34	16.78	12.92	6.25
Net Income	$963M	-$13.32M	$3.45B	$347.82M
7 Day Performance	2.21%	1.76%	1.16%	1.08%
1 Month Performance	9.83%	1.14%	1.37%	0.82%
1 Year Performance	37.02%	54.35%	62.53%	20.99%

Genmab A/S Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GMAB Genmab A/S	4.2473 of 5 stars	$31.94 +1.9%	$39.50 +23.7%	+39.0%	$19.92B	$4.13B	25.15	3,029	Analyst Upgrade
ARGX argenex	4.8115 of 5 stars	$866.11 +0.1%	$1,056.89 +22.0%	+30.5%	$54.12B	$4.25B	33.26	1,863	Analyst Downgrade
NTRA Natera	2.9179 of 5 stars	$318.35 -1.2%	$301.90 -5.2%	+95.6%	$46.13B	$2.31B	N/A	6,140	Analyst Forecast
RVMD Revolution Medicines	2.2355 of 5 stars	$206.97 +0.9%	$160.68 -22.4%	+465.5%	$43.97B	$11.58M	N/A	250	Analyst Forecast
BIIB Biogen	4.0278 of 5 stars	$207.13 -0.4%	$224.61 +8.4%	+55.5%	$30.72B	$10.03B	36.66	7,500	Positive News Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GMAB) was last updated on 8/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Genmab A/S (GMAB) Competitors